Dr. Penelope Koraka

Department of Viroscience, Erasmus Medical Centre

Artemis One Health Research B.V.

The Netherlands



Research field:



2007 Ph.D., Dengue virus specific immune response, Erasmus University, The Netherlands

2001 M.Sc., Immunology of infectious diseases, De Montfort University, Leicester, UK

1998 B.Sc., Laboratory technology, Technological Educational Institute of Athens, Athens, Greece

Publications (selected)

  1. FOOKS, A. R., P. KORAKA, R. L. DE SWART, C. E. RUPPRECHT, et al.Development of a multivalent paediatric human vaccine for rabies virus in combination with Measles-Mumps-Rubella (MMR). Vaccine, Apr 11 2014, 32(18), 2020-2021.
  2. FRAISIER, C., L. CAMOIN, S. LIM, M. BAKLI, et al. Altered protein networks and cellular pathways in severe west nile disease in mice. PLoS One,2013, 8(7), e68318.
  3. FRAISIER, C., P. KORAKA, M. BELGHAZI, M. BAKLI, et al.Kinetic analysis of mouse brain proteome alterations following Chikungunya virus infection before and after appearance of clinical symptoms.PLoS One,2014, 9(3), e91397.
  4. KORAKA, P., S. BENTON, G. VAN AMERONGEN, K. J. STITTELAAR, et al.Characterization of humoral and cellular immune responses in cynomolgus macaques upon primary and subsequent heterologous infections with dengue viruses.Microbes Infect, Jul 2007a, 9(8), 940-946.
  5. KORAKA, P., S. BENTON, G. VAN AMERONGEN, K. J. STITTELAAR, et al.Efficacy of a live attenuated tetravalent candidate dengue vaccine in naive and previously infected cynomolgus macaques. Vaccine, Jul 20 2007b, 25(29), 5409-5416.
  6. KORAKA, P., B. J. BOSCH, M. COX, R. CHUBET, et al.A recombinant rabies vaccine expressing the trimeric form of the glycoprotein confers enhanced immunogenicity and protection in outbred mice. Vaccine, Aug 6 2014, 32(36), 4644-4650.
  7. KORAKA, P., C. P. BURGHOORN-MAAS, A. FALCONAR, T. E. SETIATI, et al. Detection of immune-complex-dissociated nonstructural-1 antigen in patients with acute dengue virus infections. J Clin Microbiol, Sep 2003a, 41(9), 4154-4159.
  8. KORAKA, P., Y. P. LIM, M. D. SHIN, T. E. SETIATI, et al. Plasma levels of inter-alpha inhibitor proteins in children with acute Dengue virus infection. PLoS One,2010a, 5(4), e9967.
  9. KORAKA, P., B. E. MARTINA AND A. D. OSTERHAUS Bioinformatics in new generation flavivirus vaccines.J Biomed Biotechnol,2010b, 2010, 864029.
  10. KORAKA, P., B. E. MARTINA, J. M. ROOSE, P. P. VAN THIEL, et al.In vitro and in vivo isolation and characterization of Duvenhage virus.PLoS Pathog,2012, 8(5), e1002682.
  11. KORAKA, P., B. MURGUE, X. DEPARIS, T. E. SETIATI, et al.Elevated levels of total and dengue virus-specific immunoglobulin E in patients with varying disease severity. J Med Virol, May 2003b, 70(1), 91-98.
  12. KORAKA, P., B. MURGUE, X. DEPARIS, E. C. VAN GORP, et al.Elevation of soluble VCAM-1 plasma levels in children with acute dengue virus infection of varying severity.J Med Virol, Mar 2004, 72(3), 445-450.
  13. KORAKA, P., C. SUHARTI, T. E. SETIATI, A. T. MAIRUHU, et al.Kinetics of dengue virus-specific serum immunoglobulin classes and subclasses correlate with clinical outcome of infection. J Clin Microbiol, Dec 2001, 39(12), 4332-4338.
  14. KORAKA, P., M. M. WILLIAMS, K. DJAMIATUN, T. E. SETIATI, et al. RNA secondary structures in the proximal 3'UTR of Indonesian Dengue 1 virus strains.Virus Res, Jun 2009, 142(1-2), 213-216.
  15. LIM, S. M., A. C. BRAULT, G. VAN AMERONGEN, V. D. SEWBALAKSING, et al.Susceptibility of European jackdaws (Corvus monedula) to experimental infection with lineage 1 and 2 West Nile viruses. J Gen Virol, Jun 2014, 95(Pt 6), 1320-1329.
  16. LIM, S. M., P. KORAKA, A. D. OSTERHAUS AND B. E. MARTINA West Nile virus: immunity and pathogenesis. Viruses, Jun 2011, 3(6), 811-828.
  17. LIM, S. M., P. KORAKA, A. D. OSTERHAUS AND B. E. MARTINA Development of a strand-specific real-time qRT-PCR for the accurate detection and quantitation of West Nile virus RNA.J Virol Methods, Dec 2013a, 194(1-2), 146-153.
  18. LIM, S. M., P. KORAKA, S. VAN BOHEEMEN, J. M. ROOSE, et al.Characterization of the mouse neuroinvasiveness of selected European strains of West Nile virus. PLoS One,2013b, 8(9), e74575.
  19. MARTINA, B. E., P. KORAKA AND A. D. OSTERHAUS Dengue virus pathogenesis: an integrated view. Clin Microbiol Rev, Oct 2009, 22(4), 564-581.
  20. MARTINA, B. E., P. KORAKA AND A. D. OSTERHAUS West Nile Virus: is a vaccine needed?Curr Opin Investig Drugs, Feb 2010, 11(2), 139-146.
  21. MARTINA, B. E., P. KORAKA, P. VAN DEN DOEL, G. F. RIMMELZWAAN, et al.DC-SIGN enhances infection of cells with glycosylated West Nile virus in vitro and virus replication in human dendritic cells induces production of IFN-alpha and TNF-alpha.Virus Res, Jul 2008a, 135(1), 64-71.
  22. MARTINA, B. E., P. KORAKA, P. VAN DEN DOEL, G. VAN AMERONGEN, et al.Immunization with West Nile virus envelope domain III protects mice against lethal infection with homologous and heterologous virus.Vaccine, Jan 10 2008b, 26(2), 153-157.
  23. MARTINA, B. E., P. VAN DEN DOEL, P. KORAKA, G. VAN AMERONGEN, et al.A recombinant influenza A virus expressing domain III of West Nile virus induces protective immune responses against influenza and West Nile virus.PLoS One,2011, 6(4), e18995.
  24. VAN DE WEG, C. A., P. KORAKA, E. C. VAN GORP, A. T. MAIRUHU, et al.Lipopolysaccharide levels are elevated in dengue virus infected patients and correlate with disease severity. J Clin Virol, Jan 2012, 53(1), 38-42.

Profile Details